ClinicalTrials.gg
Not yet recruitingNCT07857226Updated Oct 19, 2026

Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer

A Phase 2 interventional study of Trastuzumab (or biosimilar) and Pertuzumab in Breast Cancer, sponsored by Hebei Medical University Fourth Hospital. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Hebei Medical University Fourth Hospital · Phase 2, Interventional, and Treatment

How we know · 9 judgments

Updated Oct 19, 2026Interventions changedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing culmerciclib in Breast Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. culmerciclib · Breast Neoplasms.

Planned enrollment
13th of 15
31 · median 40
Started
2026
with 6 others
Phase 2
9 of 15
7 open now
Primary completion
2028-06
later than 7 of 10 live
Registered
15th of 15
by date
Lead sponsor
1 of 15
Hebei Medical University Fourth Hospital

Among the 15 studies testing culmerciclib in Breast Neoplasms, this one is the 13th largest by planned enrollment, is one of 7 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 15th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 15 studies testing culmerciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About culmerciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing culmerciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This phase II single-arm study is designed to evaluate the neoadjuvant efficacy of a chemotherapy-free regimen consisting of trastuzumab, pertuzumab, Culmerciclib, and fulvestrant in patients with treatment-naïve stage II-III hormone receptor-positive, HER2-positive breast cancer. The pathological complete response (pCR) rate serves as the primary endpoint. The study aims to assess whether the pCR rate meets or exceeds that achieved with standard chemotherapy plus dual HER2-targeted therapy, and to generate preliminary evidence to support the design of a future phase III randomized controlled trial.

Read the detailed description

Patients with HR-positive/HER2-positive breast cancer have a suboptimal response to neoadjuvant chemotherapy combined with dual HER2 blockade, and an optimal treatment strategy for this population has not been established. Trastuzumab and pertuzumab are monoclonal antibodies that target HER2, while Culmerciclib is a novel CDK2/4/6 inhibitor with enhanced inhibitory activity against CDK2 and CDK4 compared with abemaciclib and palbociclib. Fulvestrant is a selective estrogen receptor downregulator. Concurrent inhibition of HER2, ER, and CDK4/6 pathways may synergistically overcome cross-talk-mediated resistance and improve antitumor efficacy. This study will explore whether the chemotherapy-sparing regimen of trastuzumab plus pertuzumab combined with fulvestrant and Culmerciclib improves pathological response in patients with previously untreated stage II-III HR-positive/HER2-positive early breast cancer.

This is a single-arm, open-label, phase II study. Approximately 31 women with stage II-III (T2-4, any N, M0 or any T, N1-3, M0 according to AJCC 8th edition) HR-positive/HER2-positive early or locally advanced breast cancer will be enrolled. Eligible participants must be treatment-naïve with histologically confirmed HER2-positive (IHC 3+ or ISH-positive) and HR-positive (ER-positive and/or PR-positive, ≥1% staining) invasive breast carcinoma. Participants will receive neoadjuvant trastuzumab (loading dose 8 mg/kg, then 6 mg/kg q3w) plus pertuzumab (loading dose 840 mg, then 420 mg q3w) for six cycles, combined with Culmerciclib180 mg orally once daily (28-day cycle) and fulvestrant 500 mg intramuscularly (day 1 and day 15 of cycle 1, then day 1 of each subsequent cycle). Premenopausal and perimenopausal participants will receive ovarian function suppression with LHRH agonists. Surgery will be performed within 3-6 weeks after completion of neoadjuvant treatment.

The primary endpoint is total pathological complete response (tpCR; ypT0/Tis, ypN0) assessed by the investigator after surgery. Secondary endpoints include breast pathological complete response (bpCR; ypT0/Tis), objective response rate (ORR) per RECIST 1.1, residual cancer burden (RCB) class, changes in Ki-67 expression from baseline to surgery, and patient-reported outcomes (EORTC QLQ-C30). Safety endpoints include the incidence of adverse events and serious adverse events. Exploratory analyses will assess the correlation between ctDNA dynamics and pCR using peripheral blood and tumor tissue specimens collected at protocol-specified time points.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria to be enrolled in this study:

  1. The participant voluntarily joins this study, signs the form, and has good compliance.
  2. Female, aged 18-75 years (at the time of signing the informed consent form), meeting one of the following criteria:

    1. Has undergone bilateral oophorectomy, or is aged ≥60 years;
    2. Aged \<60 years, with continuous amenorrhea for 12 months without pathological or physiological cause, and levels of estradiol (E2) and follicle-stimulating hormone (FSH);
    3. Premenopausal or perimenopausal female, willing to receive luteinizing hormone-releasing hormone (LHRH) agonist therapy during the study.
  3. performance status score: 0-1.
  4. >6 months.
  5. or cytologically confirmed -positive invasive breast carcinoma, with HER2 testing meeting the following requirements:

    1. HER2 positivity confirmed or verified by the pathology department of the participating center: according to the 2018 ASCO/CAP HER2 testing guidelines, HER2 positivity is defined as immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive;
    2. For multicentric tumors (multiple tumors involving more than one breast quadrant), one lesion must be sampled from each involved quadrant, and all must be confirmed or verified as HER2 positive by the pathology department of the participating center.
  6. HR-positive: ER-positive and/or PR-positive (according to the 2020 ASCO/CAP guidelines, HR positivity includes ER-positive and/or PR-positive, defined as positive staining in ≥1% of tumor cells).
  7. Clinical stage at presentation: T2-4, any N, M0 OR any T, N1-3, M0 (per AJCC 8th edition breast cancer staging system).
  8. The participant agrees to undergo breast cancer resection surgery when surgical criteria are met after therapy.
  9. Adequate major organ function, meeting the following criteria:

    1. (HGB) ≥90 g/L (without blood transfusion or use of hematopoietic stimulating factors within 7 days prior to examination);
    2. (NEUT) ≥1.5 × 10⁹/L (without blood transfusion or use of hematopoietic stimulating factors within 7 days prior to examination);
    3. count (PLT) ≥100 × 10⁹/L (without blood transfusion or use of hematopoietic stimulating factors within 7 days prior to examination);
    4. Total (TBIL) ≤1.5 × (ULN);
    5. (ALT) and aspartate aminotransferase (AST) ≤1.5 × ULN;
    6. Serum creatinine (CR) ≤1.5 × ULN or (CCr) ≥60 mL/min (calculated using the standard Cockcroft-Gault formula);
    7. Serum albumin ≥30 g/L;
    8. (PT) ≤1.5 × ULN (not receiving anticoagulant therapy);
    9. Activated partial thromboplastin time (APTT) ≤1.5 × ULN (not receiving anticoagulant therapy);
    10. International normalized ratio (INR) ≤1.5 × ULN (not receiving anticoagulant therapy);
    11. (LVEF) ≥50% assessed by echocardiography;
    12. ≤480 ms on 12-lead .
  10. Female participants of must agree to use measures (e.g., intrauterine device, contraceptive pills, or condoms) during the study and for 6 months after study completion; serum pregnancy test must be negative within 7 days prior to study enrollment, and participants must not be breastfeeding. Male participants must agree to use contraceptive measures during the study and for 6 months after study completion.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will not be enrolled in this study:

  1. Female who has received any form of prior antitumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy).
  2. Currently receiving other antitumor drug therapy.
  3. Has bilateral invasive breast cancer, inflammatory breast cancer, or occult breast cancer.
  4. Clinical stage IV breast cancer.
  5. Breast cancer not confirmed by histopathology.
  6. Has had other within the past 5 years (excluding cured carcinoma in situ of the cervix).
  7. Has severe organ dysfunction involving the heart, liver, kidney, or other major organs.
  8. Has conditions that may affect drug administration and absorption, such as dysphagia, chronic diarrhea, intestinal obstruction, etc.
  9. Has participated in another clinical drug trial within the past 4 weeks.
  10. Has a known history of allergy to any component of the study drugs; has a history of immunodeficiency, including positive test for (HIV), positive test for virus (HCV), active , or other acquired or congenital immunodeficiency diseases, or has undergone organ transplantation.
  11. Has a history of any cardiac disease, including arrhythmia requiring medical treatment or , myocardial infarction, heart failure, or any other cardiac condition deemed by the investigator to be inappropriate for participation in this study.
  12. Is pregnant or breastfeeding; is a woman of with a positive baseline pregnancy test; or is a woman of childbearing potential who is unwilling to take effective measures during the entire study period.
  13. Has concomitant diseases (including but not limited to severe hypertension, severe diabetes, active infections, etc., not controlled by medication) that, in the investigator's judgment, may pose potential harm to the participant's health or affect study completion.
  14. Has a definite history of neurological or psychiatric disorders, including epilepsy or dementia.
  15. Is considered by the investigator to be unsuitable for participation in this study for any other reason.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Trastuzumab Plus Pertuzumab in Combination with Culmerciclib and Fulvestrant Therapy

    Participants will receive neoadjuvant trastuzumab plus pertuzumab combined with Culmerciclib and fulvestrant. Trastuzumab and pertuzumab will be administered intravenously every 3 weeks for six cycles, with loading doses of 8 mg/kg and 840 mg, respectively, followed by maintenance doses of 6 mg/kg and 420 mg. The first trastuzumab infusion lasts about 90 minutes, and subsequent infusions may be shortened to 30 minutes if tolerated; pertuzumab infusions last 60 minutes initially, then 30-60 minutes. A 30- to 60-minute observation is recommended after each pertuzumab infusion. If the dosing interval reaches 6 weeks or longer, re-loading is required. Culmerciclib 180 mg is taken orally once daily in 28-day cycles with meals; missed doses should not be taken if the next dose is within 10 hours. Fulvestrant 500 mg is given intramuscularly on Cycle 1 Day 1/Day 15, then Day 1 of each subsequent cycle. Premenopausal/perimenopausal participants will receive LHRH agonists.

    Drug: Trastuzumab (or biosimilar) · Drug: Pertuzumab · Drug: Culmerciclib · Drug: Fulvestrant

Interventions

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab will be administered intravenously at an initial loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for six cycles. The first infusion will last approximately 90 minutes; if the initial infusion is well tolerated, subsequent infusions may be shortened to 30 minutes. If the interval between two consecutive trastuzumab infusions reaches 6 weeks or longer due to adverse events or other reasons, a re-loading dose of 8 mg/kg should be given over approximately 90 minutes, followed by 6 mg/kg every 3 weeks thereafter, with each infusion lasting 30 minutes, for a total of six cycles.

  • Pertuzumab will be administered intravenously at an initial loading dose of 840 mg over 60 minutes, followed by 420 mg every 3 weeks, with each infusion lasting 30 to 60 minutes, for six cycles. A 30- to 60-minute observation period is recommended after each pertuzumab infusion before proceeding with trastuzumab or chemotherapy. If the interval between two consecutive pertuzumab infusions reaches 6 weeks or longer due to adverse events or other reasons, a re-loading dose of 840 mg should be given over 60 minutes, followed by 420 mg every 3 weeks thereafter, with each infusion lasting 30 to 60 minutes, for a total of six cycles.

  • Culmerciclib will be administered orally at 180 mg once daily on a continuous schedule in 28-day cycles, taken with meals or within 2 hours after meals. Dosing at a fixed time each day is recommended. If a dose is missed and the next scheduled dose is within 10 hours, the missed dose should not be taken.

  • Fulvestrant will be administered intramuscularly at 500 mg on Day 1 and Day 15 of Cycle 1, and thereafter on Day 1 of each subsequent 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Investigator-Assessed tpCR

    Total pathological complete response (tpCR) will be assessed by the investigator after completion of neoadjuvant therapy. tpCR is defined as the percentage of participants with no evidence of invasive cancer in the breast primary tumor and no involvement of regional lymph nodes on microscopic examination after resection of the primary tumor (i.e., ypT0/Tis, ypN0 per AJCC 8th edition).

    Time frame: At surgery after completion of six treatment cycles, approximately 24 weeks after randomization

Secondary outcomes

  1. Investigator-Assessed bpCR

    Breast pathological complete response (bpCR) rate is defined as the percentage of participants with no evidence of invasive cancer in the breast primary tumor on microscopic examination after resection of the primary tumor (i.e., ypT0/Tis per AJCC 8th edition), as assessed by the investigator after completion of neoadjuvant therapy. This outcome is reported as a percentage of participants.

    Time frame: At surgery after completion of six treatment cycles, approximately 24 weeks after randomization

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as determined by the investigator according to RECIST version 1.1 during neoadjuvant therapy.

    Time frame: From randomization through surgery after six treatment cycles, approximately 24 weeks

  3. Changes in Ki-67 Expression

    Changes in Ki-67 expression are defined as the change from baseline in the percentage of Ki-67-positive tumor cells assessed by immunohistochemistry (IHC) at baseline and after completion of neoadjuvant therapy, and are reported as percentage change (%).

    Time frame: From baseline through surgery after completion of six treatment cycles, approximately 24 weeks

  4. Residual Cancer Burden (RCB) Index

    Residual Cancer Burden (RCB) index is a continuous composite measure derived by combining the primary tumor residual tumor dimensions (mm × mm), residual tumor cellularity (%), proportion of ductal carcinoma in situ (%), number of positive lymph nodes, and size of the largest lymph node metastasis (mm) using the standard RCB formula, and is reported as a unitless score, assessed pathologically after completion of neoadjuvant therapy and surgery.

    Time frame: From randomization through surgery after six treatment cycles, approximately 24 weeks

  5. Patient-Reported Outcomes (PRO)

    Patient-Reported Outcomes (PRO) will be assessed using the EORTC QLQ-C30 questionnaire according to the EORTC scoring manual. The questionnaire encompasses multiple dimensions: global health status, functional scales (physical, role, emotional, cognitive, and social functioning), symptom scales (fatigue, nausea/vomiting, and pain), and single-item measures (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties). Raw scores for each dimension are calculated as the mean of the item responses contributing to that scale and are linearly transformed to a 0-100 scale. For global health status and functional scales, higher scores indicate better functioning/quality of life; for symptom scales, higher scores indicate greater symptom severity. Changes in scores for each HRQoL dimension from baseline will be analyzed at various time points, and are reported as change in score on a 0-100 scale for each dimension.

    Time frame: From baseline through surgery after completion of six treatment cycles, approximately 24 weeks

  6. Incidence of Abnormal Physical Examination Findings

    Incidence of abnormal physical examination findings, defined as the percentage of participants with abnormal findings on physical examination, reported as a percentage of participants (%).

    Time frame: Baseline, Day 1 of each treatment cycle, end of treatment (pre-surgery).

  7. Oxygen Saturation

    Oxygen saturation, measured by pulse oximetry, reported as oxygen saturation percentage (SpO₂, %).

    Time frame: Baseline, Day 1 of each treatment cycle, end of treatment (pre-surgery).

  8. Vital Signs

    Vital signs, including body temperature (°C), systolic and diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breaths/min), measured by standardized vital sign monitoring, with each parameter reported in its respective unit.

    Time frame: Baseline, Day 1 of each treatment cycle, end of treatment (pre-surgery).

  9. 12-Lead Electrocardiogram Parameters

    12-lead electrocardiogram parameters, including heart rate (beats/min), PR interval (ms), QRS duration (ms), and QTc interval (ms), measured by 12-lead electrocardiogram, with each parameter reported in its respective unit.

    Time frame: Baseline, Day 1 of each treatment cycle, end of treatment (pre-surgery).

  10. Echocardiography Parameters

    Echocardiography parameters, including left ventricular ejection fraction (LVEF, %), measured by echocardiography, reported as a percentage (%).

    Time frame: Baseline, Day 1 of each treatment cycle, end of treatment (pre-surgery).

  11. Incidence of Abnormal Laboratory Test Findings

    Incidence of abnormal laboratory test findings, defined as the percentage of participants with abnormal findings on laboratory tests (including hematology, blood chemistry, coagulation, and urinalysis), reported as a percentage of participants (%).

    Time frame: Baseline, Day 1 of each treatment cycle, end of treatment (pre-surgery).

  12. Incidence of Adverse Events

    Incidence of adverse events (AEs), including all AEs and serious adverse events (SAEs), graded according to NCI CTCAE v5.0, reported as the percentage of participants (%) with AEs/SAEs and the number of events.

    Time frame: From the first dose of study treatment through 30 days after the last dose, approximately 28 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2028, 21 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 21 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Oct 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: Culmerciclib; removed Drug: Kurmoxilil. Arm changed Trastuzumab Plus Pertuzumab in Combination with Kurmoxilil and Fulvestrant Therapy→Trastuzumab Plus Pertuzumab in Combination with Culmerciclib and Fulvestrant Therapy
Oct 19, 2026
Title
Trastuzumab/Pertuzumab With Fulvestrant and KurmoxililCulmerciclib in HR+/HER2+ Early Breast Cancer
Oct 19, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 19, 2026
    Interventions Added Drug: Culmerciclib; removed Drug: Kurmoxilil. Arm changed Trastuzumab Plus Pertuzumab in Combination with Kurmoxilil and Fulvestrant Therapy→Trastuzumab Plus Pertuzumab in Combination with Culmerciclib and Fulvestrant Therapy
    Title Trastuzumab/Pertuzumab With Fulvestrant and KurmoxililCulmerciclib in HR+/HER2+ Early Breast Cancer
    + 2 other changes: verification date and description
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857226
Lead sponsor
Hebei Medical University Fourth Hospital
Responsible party
Li Ma (Professor and Chief Physician, Hebei Medical University Fourth Hospital) — Principal investigator
First posted
Oct 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Li Ma
Contact
47500562@hebmu.edu.cn
+86 86296348

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Culmerciclib

Start the discussion